BR9910590A - Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada - Google Patents

Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada

Info

Publication number
BR9910590A
BR9910590A BR9910590-0A BR9910590A BR9910590A BR 9910590 A BR9910590 A BR 9910590A BR 9910590 A BR9910590 A BR 9910590A BR 9910590 A BR9910590 A BR 9910590A
Authority
BR
Brazil
Prior art keywords
retina
optic nerve
blood flow
retinal diseases
treat
Prior art date
Application number
BR9910590-0A
Other languages
English (en)
Inventor
Jesse A May
Thomas R Dean
Najam A Sharif
Hwang-Hsing Chen
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of BR9910590A publication Critical patent/BR9910590A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

"COMPOSTO, PROCESSOS PARA DIMINUIR IOP, PARA MELHORAR O FLUXO SANGuìNEO PARA A EXTREMIDADE DO NERVO óPTICO E A RETINA, E PARA TRATAR DOENçAS RETINAIS, COMPOSIçõES PARA DIMINUIR IOP, PARA MELHORAR O FLUXO SANGuìNEO PARA A EXTREMIDADE DO NERVO óPTICO E A RETINA, E PARA TRATAR DOENçAS RETINAIS, PROCESSO E COMPOSIçãO PARA PROVER NEUROPROTEçãO PARA A EXTREMIDADE DO NERVO óPTICO OU A RETINA, E, PROCESSO PARA TRATAR PESSOAS SOFRENDO DE DISTúRBIOS DO SONO, DEPRESSãO, ESQUIZOFRENIA, ANSIEDADE, DISTúRBIOS RìTMICOS CIRCADIANOS E HIPERTENSãO CENTRALMENTE E PERIFERICAMENTE MEDIADA" Compostos com afinidade para receptor 5HT~ 7~ (alguns dos quais são novos) utilizáveis para diminuir IOP, melhorar o fluxo sang³íneo para a extremidade de nervo óptico e a retina, prover neuroproteção e tratar doenças retinais são descritos. Os compostos são também utilizáveis para o tratamento de distúrbios do sono, depressão, e outros distúrbios psiquiátricos, como esquizofrenia, ansiedade, distúrbio compulsivo obsessivo, distúrbios do ritmo circadiano, e hipertensão centralmente e perifericamente mediada. As composições e processos para seu uso também são descritos.
BR9910590-0A 1998-05-19 1999-05-10 Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada BR9910590A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8600698P 1998-05-19 1998-05-19
US8600598P 1998-05-19 1998-05-19
US8598998P 1998-05-19 1998-05-19
US8600298P 1998-05-19 1998-05-19
PCT/US1999/010179 WO1999059499A2 (en) 1998-05-19 1999-05-10 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders

Publications (1)

Publication Number Publication Date
BR9910590A true BR9910590A (pt) 2001-01-23

Family

ID=27491993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910590-0A BR9910590A (pt) 1998-05-19 1999-05-10 Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada

Country Status (7)

Country Link
EP (1) EP1079763A2 (pt)
JP (1) JP2002515408A (pt)
CN (1) CN1301161A (pt)
AU (1) AU3978899A (pt)
BR (1) BR9910590A (pt)
CA (1) CA2332505A1 (pt)
WO (1) WO1999059499A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9828004D0 (en) * 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
WO2000069437A1 (en) 1999-05-18 2000-11-23 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
PL358481A1 (en) * 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
KR20030095183A (ko) * 2000-03-17 2003-12-18 알콘, 인코퍼레이티드 녹내장 치료용 5-하이드록시 인다졸 유도체
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
JP2006511556A (ja) 2002-12-13 2006-04-06 アルコン，インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
TW200520760A (en) 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor

Also Published As

Publication number Publication date
WO1999059499A2 (en) 1999-11-25
CN1301161A (zh) 2001-06-27
JP2002515408A (ja) 2002-05-28
WO1999059499A3 (en) 2000-03-16
EP1079763A2 (en) 2001-03-07
AU3978899A (en) 1999-12-06
CA2332505A1 (en) 1999-11-25

Similar Documents

Publication Publication Date Title
BR9910590A (pt) Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada
BR9712824A (pt) Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
ES2253526T3 (es) Derivados de carbonilo sustituidos heterociclicos y su uso como ligandos de receptores d3 de dopamina.
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
TW200607509A (en) Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
MA27185A1 (fr) Amides substitues actifs au niveau du recepteur de cannabinoides-1
BR9908084A (pt) Composto, processo para tratar um paciente afligido por algum distúrbio do sistema nervoso central e periférico, composição farmacêutica, e, uso de um composto
WO2002066469A3 (en) Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
DK1049699T3 (da) Pyrazolotriaziner som CRF-antagonister
DE69923998D1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
DE69618047D1 (de) Verwendung von Serotonin- und Dopaminrezeptorblockern zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
ATE310517T1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
BRPI0410127A (pt) derivados de pirimidina substituìdos
WO2002066468A3 (en) Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
BR0314459A (pt) Método para baixar e controlar a pressão intra-ocular e/ou para o tratamento de mamìferos sofrendo a partir de glaucoma e composto
ATE210980T1 (de) Verwendung von indolderivaten zur behandlung von dermatologischen krankheiten, peridhren neuropathien, arthritis, allergischen oder chronisch-obstruktiven atemwegserkrankungen, glaukom und augenentzündungen
DE69028877T2 (de) Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden
BR9915803A (pt) Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
ATE253905T1 (de) Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
DK1756066T3 (da) Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet
DE69906728D1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen
ATE539763T1 (de) Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit
WO2003037260A3 (en) Methods and compositions for treating parkinson's disease
ATE428412T1 (de) Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired